Fig. 2: CRTAC1 increases the cisplatin sensitivity of NSCLC in vitro. | Cell Death & Disease

Fig. 2: CRTAC1 increases the cisplatin sensitivity of NSCLC in vitro.

From: CRTAC1 enhances the chemosensitivity of non-small cell lung cancer to cisplatin by eliciting RyR-mediated calcium release and inhibiting Akt1 expression

Fig. 2: CRTAC1 increases the cisplatin sensitivity of NSCLC in vitro.The alternative text for this image may have been generated using AI.

A The stable CRTAC1-overexpressing NSCLC cell lines H1299, HCC827, and H226 (CRTAC1) were identified by western blotting. B–D The effect of CRTAC1 on the cell viability of cisplatin-treated NSCLC cells was analyzed using the ATP assay. E, G, I The effect of CRTAC1 overexpression on apoptosis of NSCLC cell lines after exposure to 0, 10, and 20 μM cisplatin for 48 h was detected by flow cytometry. F, H, J Statistical analysis of the rate of apoptosis of NSCLC cell lines overexpressing CRTAC1 after exposure to 0, 10, and 20 μM cisplatin for 48 h. Total apoptosis rate = ratio of early apoptotic cells (lower right) + ratio of late apoptotic cells (upper right). K Western blot analysis of the effect of transient CRTAC1 knockdown in the NSCLC cell lines A549 and H1975(siCRTAC1). L, M Effect of CRTAC1 knockdown on the viability of cisplatin-treated NSCLC cells was evaluated using the ATP assay. N, P Flow cytometry was used to detect the effect of CRTAC1 knockdown on cell apoptosis after exposure to 0, 10, and 20 μM cisplatin for 48 h. A representative image of cell apoptosis is shown. O, Q The apoptosis rates of NSCLC cell lines in the CRTAC1 knockdown group and the control group were calculated after exposure to 0, 10, and 20 μM cisplatin for 48 h. The results were plotted in a histogram. (*) indicates a significant difference (P < 0.05).

Back to article page